Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Buccal Versus Vaginal Misoprostol In Combination With Foley Bulb (BEGIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03976037
Recruitment Status : Active, not recruiting
First Posted : June 5, 2019
Last Update Posted : January 31, 2020
Sponsor:
Information provided by (Responsible Party):
Helen Beatriz Gomez, Christiana Care Health Services

Brief Summary:

Combined misoprostol and Foley bulb catheter has been shown to be an effective induction method. However, optimal route of administration for misoprostol has not been established.

Therefore, the purpose of this study is to compare the effectiveness and safety of combination buccal miso-foley to combination vaginal miso-foley for third trimester cervical ripening and induction of labor.


Condition or disease Intervention/treatment Phase
Induction of Labor Drug: Misoprostol Early Phase 1

Detailed Description:

This randomized controlled trial of consenting women undergoing induction of labor with combined misoprostol and Foley catheter seeks to efficacy of vaginal versus buccal misoprostol route of administration.

This project will include 216 women presenting at Christiana Care Health System. Women will be included if they are at least 37 weeks gestation, have a singleton pregnancy, have intact membranes and are undergoing an induction of labor using a Foley catheter combined with misoprostol. Following admission, women will be randomized into either vaginal or buccal misoprostol.

Women will be randomized with equal probability to the intervention group using block randomization stratified by party.

Patients will receive 25 micrograms of misoprostol along with the insertion of a16F Foley catheter. Misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. The remainder of labor management will be at the discretion of each woman's obstetric provider.

Prior to discharge from the hospital, baseline demographic and clinical data will be obtained via chart review

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Buccal Versus Vaginal Misoprostol In Combination With Foley Bulb for Labor Induction at Term: a Randomized Controlled Trial
Actual Study Start Date : June 4, 2019
Actual Primary Completion Date : January 20, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Misoprostol

Arm Intervention/treatment
Active Comparator: Vaginal Misoprostol in combination with foley bulb

Women in the vaginal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of misoprostol per vagina along with the insertion of a16F Foley catheter with a stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.

Vaginal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.

Drug: Misoprostol

Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.

vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.

Other Name: cytotec

Active Comparator: Buccal Misoprostol in combination with foley bulb

misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.

Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.

Drug: Misoprostol

Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.

vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated.

Other Name: cytotec




Primary Outcome Measures :
  1. time to delivery (hours) defined [ Time Frame: through study completion, an average of 2 year ]
    as time from initiation of induction method to delivery time, regardless of mode of delivery.


Secondary Outcome Measures :
  1. Rate of Cesarean delivery [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  2. Time to active labor [ Time Frame: through study completion, an average of 2 year ]
    s time from initiation of induction method to dilatation ≥6cm

  3. Maternal length of stay [ Time Frame: through study completion, an average of 2 year ]
    defined as length of time from admission for induction to discharge postpartum, days

  4. Indication for cesarean delivery [ Time Frame: through study completion, an average of 2 year ]
    The reason for induction: NRFHT, arrest of dilation, arrest of descent, failed IOL, other

  5. Rate of 3rd/4th degree perineal laceration [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  6. Rate of Maternal Blood transfusion [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  7. Rate of Endometritis [ Time Frame: through study completion, an average of 2 year ]
    yes/no; fundal tenderness and fever that required treatment with antibiotics

  8. Rate of Wound separation-infection [ Time Frame: From time of delivery to time of hospital discharge; up to 6 weeks ]
    the need for additional wound closure or the need for antibiotics

  9. Rate of Venous thromboembolism [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  10. Rate of Hysterectomy [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  11. Rate of Intensive care unit admission [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  12. Rate of Maternal Death [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  13. Rate of Chorioamnionitis [ Time Frame: through study completion, an average of 2 year ]
    the presence of maternal fever ≥100·4°f in the presence of maternal or fetal tachycardia or fundal tenderness

  14. Rate of terbutaline use [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  15. Rate of Intrauterine pressure catheter use [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  16. Rate of Amnioinfusion [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  17. Rate of Analgesia use [ Time Frame: through study completion, an average of 2 year ]
    yes/no

  18. Rate of Severe respiratory distress syndrome [ Time Frame: From time of delivery to hospital discharge; up to 6 weeks ]
    defined as intubation and mechanical ventilation for a minimum of 12 hours

  19. Rate of Culture proven-presumed neonatal sepsis [ Time Frame: From time of delivery to hospital discharge; up to 6 weeks ]
    yes/no

  20. Rate of Neonatal blood transfusion [ Time Frame: From time of delivery to hospital discharge; up to 6 weeks ]
    yes/no

  21. Rate of Hypoxic ischemic encephalopathy [ Time Frame: From time of delivery to hospital discharge; up to 6 weeks ]
    yes/no

  22. Rate of Intraventricular hemorrhage grade 3 or 4 [ Time Frame: From time of delivery to hospital discharge; up to 6 weeks ]
    yes/no

  23. Rate of Necrotizing enterocolitis [ Time Frame: From time of delivery to hospital discharge; up to 6 weeks ]
    yes/no

  24. Rate of head cooling. [ Time Frame: From time of delivery to hospital discharge; up to 6 weeks ]
    yes/no

  25. Rate of NICU admission [ Time Frame: From time of delivery to hospital discharge; up to 6 weeks ]
    yes/no



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • ≥18 years of age
  • full term (≥37 weeks) gestations determined by routine obstetrical guidelines
  • singleton gestation in cephalic presentation
  • Both nulliparous and multiparous women
  • Intact membranes
  • Cervical dilation ≤2cm

Exclusion Criteria:

  • Any contraindication to a vaginal delivery or to misoprostol
  • fetal demise
  • Multifetal gestation
  • prior uterine surgery, previous cesarean section
  • Tachysystole was defined as at least 6 contractions in 10 minutes for 2 consecutive 10-minute periods
  • women with HIV, and women with medical conditions requiring an assisted second stage
  • Additional exclusion criteria were as follows: category 3 fetal heart rate tracing, hemolysis elevated liver enzymes and low platelets (HELLP) syndrome or eclampsia, growth restriction <10th percentile (based on Hadlock growth curves) with reversal of flow in umbilical artery Doppler studies, and growth restriction <5th percentile with elevated, absent, or reversal of flow in umbilical artery Doppler studies

As described in previous research (Levine LD, Downes KL, Elovitz MA, Parry S, Sammel MD, Srinivas SK. Mechanical and Pharmacologic Methods of Labor Induction: A Randomized Controlled Trial. Obstet Gynecol. 2016;128(6):1357-1364)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03976037


Locations
Layout table for location information
United States, Delaware
Christiana Care Health Systems
Newark, Delaware, United States, 19713
Sponsors and Collaborators
Christiana Care Health Services
Investigators
Layout table for investigator information
Principal Investigator: Helen B Gomez, MD Christiana Care Health Services
Publications:
Layout table for additonal information
Responsible Party: Helen Beatriz Gomez, Resident Physician, Christiana Care Health Services
ClinicalTrials.gov Identifier: NCT03976037    
Other Study ID Numbers: DDD# 604291
First Posted: June 5, 2019    Key Record Dates
Last Update Posted: January 31, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Misoprostol
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Oxytocics